Get the Stockscreener App
30.55
3.14%
-0.99
Mbx Biosciences Inc stock is traded at $30.55, with a volume of 564.05K.
It is down -3.14% in the last 24 hours and down -7.87% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$31.54
Open:
$31.6
24h Volume:
564.05K
Relative Volume:
0.66
Market Cap:
$1.37B
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-19.52
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
-1.13%
1M Performance:
-7.87%
6M Performance:
+147.77%
1Y Performance:
+67.40%
1-Day Range:
$29.63
$31.61
1-Week Range:
$29.63
$32.05
52-Week Range:
$4.8069
$35.55
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
30.55 | 1.42B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
Commit To Purchase Mbx Biosciences At $20, Earn 25% Using Options - Nasdaq
MBX Biosciences (NASDAQ:MBX) Stock Price Down 5.8%Here's What Happened - MarketBeat
MBX Biosciences initiated with a sell at Goldman Sachs - MSN
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Mbx Biosciences stock hits all-time high of 34.85 USD By Investing.com - Investing.com Nigeria
MBX Biosciences (NASDAQ:MBX) Stock Price Up 10.8%Still a Buy? - MarketBeat
Mbx Biosciences stock hits all-time high of 34.85 USD - Investing.com
MBX Biosciences price target raised to $50 from $45 at Stifel - MSN
Take Profit: Will MBX Biosciences Inc stock keep outperforming rivalsJuly 2025 Pullbacks & Capital Efficiency Focused Ideas - moha.gov.vn
MBX Biosciences, Inc.(NasdaqGS:MBX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) added to NASDAQ Biotechnology Index - marketscreener.com
Dip Buying: Will MBX Biosciences Inc stock keep outperforming rivalsJuly 2025 Intraday Action & Stock Portfolio Risk Control - moha.gov.vn
MBX Biosciences (NASDAQ:MBX) Upgraded at Wall Street Zen - MarketBeat
How sustainable is MBX Biosciences Inc. stock dividend payoutPortfolio Profit Report & Safe Entry Point Alerts - Улправда
Stifel maintains MBX Biosciences (MBX) buy recommendation - MSN
Will MBX Biosciences Inc. stock attract ESG investorsWeekly Profit Summary & Detailed Earnings Play Alerts - Улправда
MBX Biosciences stock price target raised to $50 by Stifel on strong trial data By Investing.com - Investing.com Nigeria
Stifel Maintains MBX Biosciences (MBX) Buy Recommendation - Nasdaq
MBX Biosciences stock price target raised to $50 by Stifel on strong trial data - Investing.com South Africa
Is MBX Biosciences Inc. stock positioned well for digital economyJuly 2025 Trends & AI Driven Stock Reports - DonanımHaber
Aug Technicals: Will MBX Biosciences Inc. stock attract ESG investorsMarket Activity Recap & AI Enhanced Trading Alerts - Улправда
Is MBX Biosciences Inc. stock undervalued vs historical averagesJuly 2025 Sector Moves & High Accuracy Trade Signal Alerts - Улправда
S P Trends: What catalysts could drive MBX Biosciences Inc stock higherEarnings Growth Summary & Free Weekly Watchlist of Top Performers - moha.gov.vn
MBX Biosciences (MBX) faces platform validation challenge as near-term hypoglycemia data catalyst in Q2 2026 may lack differentiation - MSN
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation - Finviz
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 - The Manila Times
20 Stocks That Will Double in 2026 - Insider Monkey
EcoR1 Capital LLC Lowers Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences (NASDAQ:MBX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Walleye Capital LLC Increases Stock Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences: Testing 2026 May Deliver Another Year Of Share Price Gains - Seeking Alpha
MBX Biosciences, Inc. $MBX Stake Increased by Stempoint Capital LP - MarketBeat
MBX Biosciences (NASDAQ:MBX) Shares Down 5.6%Should You Sell? - MarketBeat
Resolute Capital Asset Partners LLC Acquires New Position in MBX Biosciences, Inc. $MBX - MarketBeat
Certain Common Stock of MBX Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Certain Stock Options of MBX Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
MBX Biosciences (NASDAQ:MBX) Earns Sell Rating from Analysts at The Goldman Sachs Group - MarketBeat
MBX Biosciences (NASDAQ:MBX) Shares Gap DownHere's What Happened - MarketBeat
Goldman Sachs initiates coverage of MBX Biosciences (MBX) with sell recommendation - MSN
Goldman Sachs Initiates Coverage of MBX Biosciences (MBX) with Sell Recommendation - Nasdaq
MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM ExitWhat's Changed - Yahoo Finance
Goldman Sachs initiates MBX Biosciences stock with Sell rating on platform concerns - Investing.com Nigeria
Goldman Sachs initiates MBX Biosciences stock with Sell rating on platform concerns By Investing.com - Investing.com South Africa
MBX Biosciences drops 4% in premarket trading after Goldman initiates with sell - MSN
Goldman Sachs Initiates Coverage on MBX with Sell Rating | MBX S - GuruFocus
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):